JLE

Bulletin du Cancer

MENU

Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center Volume 88, issue 12, Décembre 2001

Figures

See all figures

Authors
Centre Léon-Bérard, Service 2BS, 28, rue Laennec, 69373 Lyon Cedex 08.

We have examined 82 patients with hormonoresistant prostate cancer in a retrospective study. Bone and lymph node metastases were observed in 94% and 30% of patients respectively. However, the visceral metastases were frequent: liver (17%), lung (7%), bone marrow (4%), meningitis (4%). PSA is constantly high but 28% of the patients have elevated NSE, which is correlated with lymph node or visceral metastases. ACE is elevated in 27% of cases. Objective and palliative effect of chemotherapy is marked for weekly doxorubicin, prednisone with mitoxantrone and etoposide associated with platin-salts for prostatic carcinoma with neuroendocrine differentiation. This study suggests the presence of different subpopulations of patients with specific evolutive patterns, thus further specific therapy should be evaluated.